Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Videx; Belgium: Videx; Bulgaria: Videx; Cyprus: Videx; Czech Republic: Videx; Denmark: Videx; Estonia: Videx; Finland: Videx; France: Videx; Germany: Videx; Greece: Videx; Hungary: Videx; Ireland: Videx; Italy: Videx; Latvia: Videx; Lithuania: Videx; Luxembourg: Videx; Malta: Videx; Netherlands: Videx; Poland: Videx; Portugal: Videx; Romania: Videx; Slovakia: Videx; Slovenia: Videx; Spain: Videx; Sweden: Videx; UK: Videx.

North America

Canada: Videx; USA: Didanosine, Videx.

Latin America

Argentina: DDI Martian, Didanosina, Dinosin, Videx; Brazil: Didanosin, Videx; Mexico: Didanosina, Didasten, Dinocin, Videx.


Japan: Videx.

Drug combinations


Didanosine: C~10~H~12~N~4~O~3~. Mw: 236.23. Inosine, 2′,3′-dideoxy-. CAS-69655-05-6 (1990).

Pharmacologic Category

Antiretrovirals; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors. (ATC-Code: A03AA07).

Mechanism of action

Inhibits HIV replication in vitro in both T-cells and monocytes due to its conversion within the cell to mono-, di-, and triphosphates of ddA which act as substrate and inhibitor of HIV reverse transcriptase substrate and inhibitor of HIV reverse transcriptase thereby blocking viral DNA synthesis and suppressing HIV replication.

Therapeutic use

Treatment of HIV infection (in combination with at least two other antiretroviral agents).

Pregnancy and lactiation implications

Pregnant women may be at increased risk of lactic acidosis and liver damage. Use during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus. Contraindicated during lactation.

Unlabeled use


Hypersensitivity to didanosine or any component of the formulation.

Warnings and precautions

May cause fat redistribution. Lactic acidosis and severe hepatomegaly with steatosis reported. Immune reconstitution syndrome may develop. Retinal changes and optic neuritis reported. Pancreatitis reported. Peripheral neuropathy may occur. Hepatotoxicity reported in HIV patients treated with didanosine in combination with hydroxyurea and stavudine (this combination should be avoided). Caution in heart failure, edema and/or patients on sodium-restricted diets, hepatic impairment, hyperuricemia or renal impairment.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart